显微手术与血管内治疗破裂颅内动脉瘤的成本比较:倾向性校正分析
在单一四级中心回顾性分析384例动脉瘤性蛛网膜下腔出血患者,234例(61%)接受显微手术、150例(39%)接受血管内治疗。倾向性评分校正后,显微手术与医疗费用较血管内治疗低37244美元独立相关(P<.001)。作者认为显微手术治疗aSAH的总医疗费用低于血管内治疗。
要点
- 384例aSAH中,显微手术234例(61%),血管内治疗150例(39%)。
- 有随访数据的患者中,血管内治疗平均总费用159406美元(n=59)高于显微手术114366美元(n=105)(P<.001)。
- 倾向性校正后显微手术费用较血管内治疗低37244美元(P<.001)。
核心结论
- 显微手术治疗aSAH与低于血管内治疗的总体医疗费用相关。
- 血管内治疗后的动脉瘤监测、再治疗及装置费用值得未来研究关注。
研究设计与样本
- 单中心回顾性研究,纳入2014年7月1日至2019年7月31日接受治疗的aSAH患者。
- 按主要治疗方式分为显微手术组与血管内治疗组,共384例。
- 主要结局为采用倾向性校正分析的总费用差异,包括住院、出院机构及所有随访费用。
主要发现
- 384例中显微手术234例(61%),血管内治疗150例(39%)。
- 索引住院平均费用血管内治疗为103980美元,显微手术为94476美元,血管内治疗边际性高出9504美元(P=.047)。
- 有随访数据的患者中,平均总费用血管内治疗为159406美元(n=59),显微手术为114366美元(n=105),血管内治疗高出45040美元(P<.001)。
- 倾向性评分校正年龄、性别、合并症、GCS评分、Hunt和Hess分级、Fisher分级、动脉瘤及类型/大小/位置后,线性回归显示显微手术与费用较血管内治疗低37244美元独立相关(P<.001)。
- 逐项费用分析提示差异源于动脉瘤再治疗率及长期监测的不同。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In specialized neurosurgical centers, open microsurgery is routinely performed for aneurysmal subarachnoid hemorrhage (aSAH). OBJECTIVE: To compare the cost of endovascular vs microsurgical treatment for aSAH at a single quaternary center. METHODS: All patients undergoing aSAH treatment from July 1, 2014, to July 31, 2019, were retrospectively reviewed. Patients were grouped based on primary treatment (microsurgery vs endovascular treatment). The primary outcome was the difference in total cost (including hospital, discharge facility, and all follow-up) using a propensity-adjusted analysis. RESULTS: Of 384 patients treated for an aSAH, 234 (61%) were microsurgically treated and 150 (39%) were endovascularly treated. The mean cost of index hospitalization for these patients was marginally higher ($9504) for endovascularly treated patients ($103 980) than for microsurgically treated patients ($94 476) ( P = .047). For the subset of patients with follow-up data available, the mean total cost was $45 040 higher for endovascularly treated patients ($159 406, n = 59) than that for microsurgically treated patients ($114 366, n = 105) ( P < .001). After propensity scoring (adjusted for age, sex, comorbidities, Glasgow Coma Scale score, Hunt and Hess grade, Fisher grade, aneurysms, and type/size/location), linear regression analysis of patients with follow-up data available revealed that microsurgery was independently associated with healthcare costs that were $37 244 less than endovascular treatment costs ( P < .001). An itemized cost analysis suggested that this discrepancy was due to differences in the rates of aneurysm retreatment and long-term surveillance. CONCLUSION: Microsurgical treatment for aSAH is associated with lower total healthcare costs than endovascular therapy. Aneurysm surveillance after endovascular treatments, retreatment, and device costs warrants attention in future studies.
引用
- Labib MA, Rumalla K, Karahalios K, et al. Cost Comparison of Microsurgery vs Endovascular Treatment for Ruptured Intracranial Aneurysms: A Propensity-Adjusted Analysis. Neurosurgery. 2022. PMID: 35876676. doi:10.1227/neu.0000000000002061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。